(Reuters) -Cassava Sciences said on Tuesday its Alzheimer's drug simufilam, which has been at the center of regulatory ...

Shares of Cassava Sciences SAVA plunged 32.1% on Tuesday after the company announced that its lead pipeline candidate, ...

Discover how Alzheimer's disease progresses from mild cognitive changes to severe symptoms, with explanations of each stage ...

Cassava Sciences has given up on simufilam in Alzheimer’s disease. | Cassava Sciences has given up on simufilam in ...

The company ended 2024 with just under $127 million in cash reserves, and nothing in its pipeline beyond the Alzheimer's ...

US biotech Cassava Sciences (Nasdaq: SAVA) will shut down development of its lead Alzheimer’s disease candidate, simufilam, after the treatment failed a second late-stage trial. Top-line results from ...

and therefore does not provide sufficient data on the impact of these medications on later-stage Alzheimer's." Fillit added that this new research opens the door for further exploration of ...

The new findings center on a subset of 22 participants who received amyloid-removing drugs the longest, on average eight ...

Cassava Sciences is ending simufilam development for Alzheimer's after Phase 3 trials failed. The company is shifting focus ...

Cassava Sciences (SAVA) stock falls as the company halts Alzheimer's drug program after trial failures. Read more here.

For the first time, scientists say, they have evidence that using a biologic drug to remove sticky beta amyloid plaques from ...

An early Alzheimer's treatment that removes amyloid plaques from the brain many years before symptoms arise may help delay ...